Withdrawal of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Elicits Oxidative Stress and Induces Endothelial Dysfunction in Mice
- 26 July 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 91 (2) , 173-179
- https://doi.org/10.1161/01.res.0000028004.76218.b8
Abstract
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) improve endothelial function. We determined whether withdrawal of statin therapy affects endothelium-dependent relaxation in mice and studied the underlying mechanism. Mice were treated with daily injections of cerivastatin (2 mg/kg per day SC), atorvastatin (1 and 10 mg/kg per day SC), or placebo. Vascular reactivity was studied in aortic rings from these mice after 10 days of treatment and after cessation of therapy for several days. Both statins improved endothelium-dependent relaxation to acetylcholine. Compared with control, withdrawal of statin treatment transiently (from day 4 to 7) attenuated endothelium-dependent relaxation. In vessels from animals subjected to atorvastatin withdrawal, the antioxidant tiron restored relaxations. Vascular superoxide anion generation was unaffected by statin therapy but was increased during withdrawal. In mice lacking the gp91phox subunit of the NADPH oxidase, no attenuation of acetylcholine-induced relaxation and no increase in superoxide generation were observed after withdrawal of atorvastatin. In human umbilical vein endothelial cells, statins, which decrease the membrane association of NADPH oxidase–activating Rac-1, increased the activity of this GTPase in whole-cell lysates. Withdrawal of statins induced a translocation of Rac-1 from the cytosol to the membrane and transiently increased NADPH-induced lucigenin chemiluminescence in membrane preparations. Rac-1 inactivation by Clostridium difficile toxin B inhibited the cerivastatin-induced oxygen radical production in human umbilical vein endothelial cells. These observations indicate that the withdrawal of statins induces endothelial dysfunction. The underlying mechanism involves activation of a gp91phox-containing NADPH oxidase by Rac-1 and the subsequent scavenging of endothelium-derived NO by superoxide anions generated from this enzyme.Keywords
This publication has 24 references indexed in Scilit:
- Vascular endothelial growth factor induces manganese‐superoxide dismutase expression in endothelial cells by a Racl‐regulated NADPH oxidase‐dependent mechanismThe FASEB Journal, 2001
- Mechanism of NADPH Oxidase Activation by the Rac/Rho-GDI ComplexBiochemistry, 2001
- Statin therapy: where are we? where do we go next?The American Journal of Cardiology, 2001
- Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular diseaseCardiovascular Research, 2001
- Manganese superoxide dismutase in diseaseFree Radical Research, 2001
- Direct Vascular Effects of HMG-CoA Reductase InhibitorsTrends in Cardiovascular Medicine, 2000
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Protective roles of cytokines against radiation: Induction of mitochondrial MnSODBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1995
- Tolerance, rebound, and time-zero effect of nitrate therapyThe American Journal of Cardiology, 1992
- Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1Nature, 1991